Pembroke Management LTD lifted its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,992,432 shares of the company's stock after acquiring an additional 84,087 shares during the quarter. Cellebrite DI accounts for 5.6% of Pembroke Management LTD's portfolio, making the stock its 2nd largest position. Pembroke Management LTD owned about 0.97% of Cellebrite DI worth $43,893,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of Cellebrite DI by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after acquiring an additional 75,092 shares during the last quarter. Telemark Asset Management LLC purchased a new position in Cellebrite DI in the 3rd quarter worth about $6,736,000. Two Sigma Advisers LP increased its stake in Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock worth $22,584,000 after buying an additional 120,000 shares during the period. Harbor Capital Advisors Inc. increased its stake in Cellebrite DI by 65.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock worth $3,473,000 after buying an additional 62,320 shares during the period. Finally, State Street Corp increased its position in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after purchasing an additional 30,052 shares during the period. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Stock Up 0.3 %
Shares of Cellebrite DI stock traded up $0.05 on Friday, reaching $19.12. The stock had a trading volume of 3,548,554 shares, compared to its average volume of 2,077,086. The company has a 50 day moving average price of $22.55 and a 200 day moving average price of $19.33. Cellebrite DI Ltd. has a 1 year low of $10.24 and a 1 year high of $26.30. The stock has a market capitalization of $3.94 billion, a P/E ratio of -13.76, a P/E/G ratio of 4.40 and a beta of 1.47.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CLBT has been the topic of a number of research reports. Craig Hallum raised their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Friday, February 14th. Lake Street Capital raised their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $23.43.
Get Our Latest Report on CLBT
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
